Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | RBP4 | P02753 | 1/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988200 | 0.87 | HSD11B1 (0.70) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL1375423 | 0.82 | EPHX2 (0.68) | HSD11B1GAARBP4TRPV1EPHX2 | |
| SCHEMBL3213486 | 0.82 | TRPV1 (0.69) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL3320963 | 0.82 | HSD11B1 (0.57) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL4841943 | 0.82 | HSD11B1 (0.63) | HSD11B1GAARBP4TRPV1TRPA1 | |
| Hydrochloric Acid SCHEMBL1375801 | 0.81 | HSD11B1 (0.65) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL3222359 | 0.81 | HSD11B1 (0.62) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL16690887 | 0.81 | RBP4 (1.00) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL3205429 | 0.81 | GAA (0.64) | HSD11B1GAARBP4TRPV1TRPA1 | |
| SCHEMBL1252470 | 0.81 | TRPV1 (0.66) | HSD11B1GAARBP4TRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2007090134-A2 | USE OF VANILLOID RECEPTOR-1 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-08-09 | — | — | WO | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20200215085-A1 | Method to Abate Acute Airway Hypersensitivity and Asthma Attacks | AAZEINTX INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| WO-2019014748-A1 | METHOD TO ABATE ACUTE AIRWAY HYPERSENSITIVITY AND ASTHMA ATTACKS | UTI LIMITED PARTNERSHIP (CA) | 2019-01-24 | — | — | WO | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120310140-A1 | DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY | SPINAL MODULATION, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010015260-A2 | ADMINISTRATION BY INFUSION FOR THE TREATMENT OF ISCHEMIC EFFECTS | NEUROKEY A/S (DK) | 2010-02-11 | — | — | WO | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | AMGEN INC. | 2006-12-14 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
| CN-1798735-A | 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase | NOVO NORDISK AS (DK) | 2006-07-05 | — | — | CN | disclosed |
| EP-1651638-A1 | PYRIDYL PIPERAZINYL UREAS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| US-20050049241-A1 | Pyridyl piperazinyl ureas | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005014580-A1 | PYRIDYL PIPERAZINYL UREAS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | HSD11B1 137/4885GAA 1839/4885RBP4 4739/4885 |
| US-20050049241-A1 | Pyridyl piperazinyl ureas | VIPR1, UTS2R, GPR17 | HSD11B1 4722/4885GAA 4400/4885RBP4 1657/4885 |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | CNR1, CNR2, AVPR1A | HSD11B1 2276/4885GAA 2627/4885RBP4 2895/4885 |
| US-20060281718-A1 | Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent | VRK1, VIPR1, AVPR1A | HSD11B1 1691/4885GAA 3330/4885RBP4 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.